Evidence map›Paper›PMID 27505125›Full record

ArticleAntioxidants & redox signaling2017

Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.

Sara Vandenwijngaert, Melissa Swinnen, Ann-Sophie Walravens, Manu Beerens, Hilde Gillijns, Ellen Caluwé, Robert E Tainsh, Daniel I Nathan, Kaitlin Allen, Peter Brouckaert and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants & redox signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Sara Vandenwijngaert1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Melissa Swinnen2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Ann-Sophie Walravens2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Manu Beerens2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Hilde Gillijns2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Ellen Caluwé2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Robert E Tainsh1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Daniel I Nathan1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Kaitlin Allen1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Peter Brouckaert3 Department of Biomedical Molecular Biology, Ghent University and Flanders Institute for Biotechnology , Ghent, Belgium .
Jozef Bartunek2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Marielle Scherrer-Crosbie5 Cardiovascular Research Center, Massachusetts General Hospital Research Institute and Harvard Medical School , Boston, Massachusetts.
Kenneth D Bloch1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Donald B Bloch1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Stefan P Janssens2 Department of Cardiovascular Sciences, KU Leuven , Leuven, Belgium .
Emmanuel S Buys1 Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital Research Institute and Harvard Medical School , Anesthesia Center for Critical Care Research, Boston, Massachusetts.
Massachusetts General Hospital · USKU Leuven · BEOnze Lieve Vrouwziekenhuis Hospital · BEVlaams Instituut voor Biotechnologie · BE

Funding

Modulation of Hepcidin-Ferroportin Signaling using Small MoleculesR01DK082971 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BLOCH, DONALD B, PETERSON, RANDALL T · 2009 to 2018
$4.5M
Role of Soluble Guanylate Cyclase Alpha 1 in Open Angle GlaucomaR01EY022746 · NEI · MASSACHUSETTS GENERAL HOSPITAL · PI BUYS, EMMANUEL S · 2012 to 2016
$2.0M
NEI NIH HHS R01 EY022746NIDDK NIH HHS R01 DK082971
6 · The paper itself

Abstract

aimsThe use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of doxorubicin-induced cardiotoxicity.

resultsDoxorubicin administration (20 mg/kg, intraperitoneally [IP]) reduced cardiac sGC activity in wild-type (WT) mice. To investigate whether decreased sGC activity contributes to doxorubicin-induced cardiotoxicity, we studied mice with cardiomyocyte-specific deficiency of the sGC α1-subunit (mice with cardiomyocyte-specific deletion of exon 6 of the sGCα1 allele [sGCα1

Indexed as

AnimalsAntibiotics, AntineoplasticCardiotoxicityDisease Models, AnimalDoxorubicinEnzyme ActivationGene ExpressionHeart DiseasesMiceMice, KnockoutMutationMyocytes, CardiacReactive Oxygen SpeciesSoluble Guanylyl CyclaseVentricular DysfunctionAntibiotics, AntineoplasticDoxorubicinReactive Oxygen SpeciesSoluble Guanylyl Cyclasecardiomyopathycardiovascularchemotherapycyclic nucleotidesdoxorubicinsoluble guanylate cyclase

Identifiers

PMID27505125
PMCPMC5278809
OpenAlexW2520145022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.